This content is only available as a PDF.

Author notes

Sources of Support: Vivek Subbiah is supported by National Institutes of Health grant R01CA242845; MD Anderson is supported by Cancer Center Support Grant (P30 CA016672).

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Competing Interests

Conflicts of interest: Vivek Subbiah reports unrelated research grants from LOXO Oncology/Eli Lilly, Roche/Genentech, Bayer, GlaxoSmithKline, Nanocarrier, Vegenics, Celgene, Northwest Biotherapeutics, Berghealth, Incyte, Fujifilm, D3, Pfizer, Multivir, Amgen, Abbvie, Alfa-sigma, Agensys, Boston Biomedical, Idera Pharma, Inhibrx, Exelixis, Blueprint Medicines, Altum, Dragonfly Therapeutics, Takeda, National Comprehensive Cancer Network, NCI-CTEP, UT MD Anderson Cancer Center, Turning Point Therapeutics, Boston Pharmaceuticals, Novartis, Pharmamar, and Medimmune; an advisory board/consultant position with LOXO Oncology/ Eli Lilly, Relay Therapeutics, Blueprint medicines, Helsinn, Incyte, QED Pharma, Daiichi-Sankyo, Signant Health, Novartis, and Medimmune; travel funds from Pharmamar, Incyte, ASCO, and ESMO; other support from Medscape; all outside the submitted work.

Article PDF first page preview

Article PDF first page preview